GLP-1: Sustainable Solution or Growing Dependence?

In recent years, GLP-1 drugs have become one of the most talked-about medical innovations in metabolic health. Originally developed for diabetes management, these medications are now widely recognized for their remarkable ability to help patients lose weight and improve overall cardiometabolic health.

However, like any powerful therapy, GLP-1 drugs come with both significant benefits and potential risks. Understanding their history, current usage trends, and future prospects helps provide a balanced view of this rapidly evolving pharmaceutical category.

---

The Discovery and Early Development of GLP-1

GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the intestine after food consumption. It plays an important role in glucose regulation by stimulating insulin secretion, suppressing glucagon release, slowing gastric emptying, and promoting satiety signals in the brain.¹

Scientists began studying GLP-1 in the late 20th century after recognizing its ability to significantly improve blood glucose control. However, the natural hormone breaks down rapidly in the body, making it difficult to use as a direct therapy. Researchers therefore developed GLP-1 receptor agonists, drugs that mimic the effects of GLP-1 but remain active for longer periods.

The first GLP-1 receptor agonist was approved in 2005 for the treatment of type 2 diabetes, marking a major milestone in metabolic medicine. Since then, several new drugs have been introduced with improved effectiveness and dosing convenience.

Important milestones include²:

Year	Drugs	Indication
2005	Exenatide	first GLP-1 drug for diabetes
2010	Liraglutide	once-daily GLP-1 therapy
2014	Saxenda	first GLP-1 drug approved for obesity
2017	Semaglutide	once-weekly injection for diabetes
2021	Wegovy	high-dose semaglutide for weight loss
2022	Tirzepatide	dual GLP-1 and GIP receptor agonist

These developments greatly improved treatment convenience and effectiveness, paving the way for widespread adoption.

---

Explosive Growth in GLP-1 Usage

Although GLP-1 drugs were originally prescribed mainly for diabetes management, their strong weight-loss effects dramatically increased demand in recent years.

Prescription data illustrates this rapid expansion. Between 2018 and 2023, GLP-1 receptor agonist use increased nearly 5-fold, rising from 745 users per 100,000 individuals to 3,572 users per 100,000.³

In the United States, the adoption rate has also increased sharply. According to national health survey data, 26.5% of adults with diagnosed diabetes used GLP-1 injectable medications in 2024.⁴

Financial spending reflects the same dramatic trend. Annual U.S. spending on GLP-1 drugs increased from $13.7 billion in 2018 to approximately $71.7 billion in 2023, representing a more than 500% increase within five years.⁵

This surge in usage has been driven largely by drugs such as semaglutide and tirzepatide, which demonstrate stronger weight-loss outcomes compared with earlier treatments.

---

Key Medical Benefits of GLP-1

Although GLP-1 drugs have become famous for weight loss, their clinical benefits extend beyond obesity treatment.

1. Blood Sugar Control in Diabetes

GLP-1 receptor agonists stimulate insulin release when blood glucose levels are elevated while suppressing glucagon secretion, helping stabilize blood sugar levels in individuals with type 2 diabetes.¹

2. Significant Weight Reduction

Clinical trials show that certain GLP-1 drugs can help patients lose 15–25% of their body weight averagely, making them one of the most effective pharmacological weight-loss treatments available.⁶

3. Cardiovascular Protection

Research indicates that GLP-1 therapies can reduce major adverse cardiovascular event (MACE) by about 14% potentially via improving blood pressure, lipid profile, inflammatory markers, and endothelial functions.⁷

4. Improved Metabolic Health

These medications also improve several markers of metabolic syndrome, including waist circumference, insulin resistance, and liver fat accumulation.

---

Future Developments in GLP-1 Therapy

The success of GLP-1 medications has sparked intense pharmaceutical innovation:

Oral GLP-1 Drugs

While many current GLP-1 therapies require injections, new oral formulations are being developed to enhance patient convenience and adherence. The U.S. Food and Drug Administration (FDA) has recently approved an oral version of Wegovy for weight management, making it the first pill of its kind to receive regulatory approval. ⁸

Multi-Hormone Therapies

Next-generation therapies combine GLP-1 with other metabolic hormones such as GIP and glucagon, producing even stronger metabolic effects.

New Therapeutic Targets

Researchers are also exploring GLP-1 drugs for additional health conditions, including:

• Non-alcoholic fatty liver disease

• Cardiovascular disease

• Chronic kidney disease

• Neurodegenerative disorders

If these applications prove successful, GLP-1 therapies could become one of the most versatile drug classes in modern medicine.

---

Potential Side Effects and Safety Concerns

Despite their benefits, GLP-1 medications are not without risks. Like many powerful treatments, they can cause side effects.

Common Side Effects⁹

The most frequently reported issues involve gastrointestinal discomfort which can affects up to 60% if the patients, including:

• Nausea

• Vomiting

• Diarrhea

• Constipation

• Reduced appetite

Pancreatitis and Gallbladder Risk

Rare cases of acute pancreatitis have been reported among GLP-1 users. Rapid weight loss associated with these medications may also increase the risk of gallstones.

Weight Regain After Stopping Treatment

Another concern is that patients often regain weight after discontinuing the medication, suggesting that long-term therapy may be necessary to maintain benefits.

---

A Bigger Question:

Long-Term Solution or Long-Term Dependence?

The remarkable success of GLP-1 drugs raises important questions about the future of metabolic healthcare. On one hand, these medications offer a powerful solution to the global obesity crisis, helping millions of people achieve meaningful weight loss and improved metabolic health.

On the other hand, their growing popularity raises concerns about long-term reliance. If individuals achieve weight loss primarily through medication, will they still be motivated to adopt healthier diets and lifestyle habits? Or could society eventually become dependent on pharmaceutical solutions to manage lifestyle-related diseases?

Perhaps the most important question moving forward

Will GLP-1 drugs become a revolutionary tool that empowers millions to regain control of their metabolic health, or will society eventually grow reliant on them as a long-term solution to lifestyle-related diseases?

Find Out More

---

Aqurate Ingredients is an international player in supplying functional ingredients and providing innovative solutions to the food & beverage, nutraceutical, pharmaceutical and cosmeceutical industry. We believe, a satisfied customer is a repeat customer.